Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad ...

Stocks recently featured in the blog include: Johnson & Johnson JNJ, Pfizer PFE, Roche RHHBY, AbbVie ABBV and Sanofi SNY. Here are highlights from Monday’s Analyst Blog: Pharma Stock Roundup: Q3 ...

Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a ...

Pfizer itself sued a “soon-to-be former employee” in 2021, accusing the staffer of uploading more than 12,000 files to a personal Google Drive account, some of which could contain confidential ...

Pfizer (PFE-0.47%) and Johnson & Johnson (JNJ 0.22%) are industry stalwarts with long track records, generous dividends, and solid growth prospects.

Johnson & Johnson, Pfizer, Eli Lilly and other big pharmas are backing this San Diego biotech with $175M Local biotech Capstan Therapeutics exceeded its fundraising goal by $50 million despite a ...

In 1989, Johnson & Johnson sold its talc subsidiary. Instead of taking the opportunity to transition Johnson’s Baby Powder entirely to cornstarch, as other giants like Pfizer were doing, the company ...